Everolimus is approved for the treatment of metastatic BC32 and the AKT1 inhibitor Capivasertib has demonstrated anti-tumour activity in most patients with metastatic AKT1-mutant tumours enroled in the NCI-MATCH trial33. The gene discussed is AKT1; the disease is neoplasm.